Form 8-K - Current report:
SEC Accession No. 0001390478-25-000004
Filing Date
2025-03-20
Accepted
2025-03-20 16:07:39
Documents
14
Period of Report
2025-03-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sls-20250320.htm   iXBRL 8-K 31725
2 EX-99.1 sls-202503208xkexhibit991.htm EX-99.1 69921
  Complete submission text file 0001390478-25-000004.txt   235539

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sls-20250320.xsd EX-101.SCH 1812
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sls-20250320_lab.xml EX-101.LAB 21629
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sls-20250320_pre.xml EX-101.PRE 12529
16 EXTRACTED XBRL INSTANCE DOCUMENT sls-20250320_htm.xml XML 2733
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 25756491
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)